Alzamend Neuro, Inc. Common Stock

ALZNNASDAQ • USD
ThemeBiotech - Drug Development›Neuroscience & CNS
1.29 USD
↘ 0.08 (5.84%)AT CLOSE (11:59 AM EDT)
1.29
↗ 0.00 (0.08%)
POST MARKET (AS OF 07:48 PM EDT)
Post Market
AS OF 07:48 PM EDT
1.29
↗ 0.00 (0.08%)
🔴Market: CLOSED

ALZN is currently priced at $1.37. There is a divergence between signals — technical indicators rate "Buy" but underlying fundamentals lean "Sell". Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation side, ALZN appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Jun 25, 2026.

Open?$1.32
High?$1.37
Low?$1.24
Prev. Close?$1.37
Volume?205.4K
Avg. Volume?80.1K
VWAP?$1.32
Rel. Volume?2.56x
Bid / Ask
Bid?$1.23 × 100
Ask?$1.35 × 1.2K
Spread?$0.12
Midpoint?$1.29
Valuation & Ratios
Market Cap?4.9M
Shares Out?3.8M
Float?3.8M
Float %?98.6%
P/E Ratio?N/A
P/B Ratio?2.25
EPS?-$2.01
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Themes
Biotech - Drug Development›Neuroscience & CNSLongevity & Aging›Age-Related Therapeutics
Employees
7
Market Cap
5.2M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.alzamend.com
Listed
2021-06-15
Address
480 PEACHTREE ROAD NE, SECOND FLOOR
ATLANTA, GA 30326
Phone: 844-722-6333
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
65
Piotroski F-Score?0/9Weak
Altman Z-Score?-25.93Distress
Confidence?45%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?3.34%Low
Short Interest?125.4K
Days to Cover?2.4
Free Float3.8M
Avg Daily Volume53.2K
Settlement Date2026-06-15
Financial Health
Current Ratio?1.99Adequate
Quick Ratio?1.99Adequate
Cash Ratio?1.46Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
69
2.25CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.3CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-349.4%WEAK▾
ROA?
S&P
3
-188.8%WEAK▾
Cash Flow & Enterprise
FCF?$-6169224
Enterprise Value?$2.2M
Fundamentals ratios updated end of day
MarketsMoversWatchlist